I

Immunic Therapeutics

Clinical-stage biopharma developing oral autoimmune therapies

HR Business Partner - HR

HR Operations & Coordination +1Confirmed live in the last 24 hours
Full-timeGräfelfing, GermanyNo salary listed

About the Job

Requirements

  • An advanced degree (MBA, MHR, or equivalent) is preferred.
  • At least 12 years of progressive HR leadership experience, including HR business partner and HR operations experience within biotechnology or life sciences.
  • Direct, hands-on human resources experience in the European Union, supporting European employees and entities as part of a global HR team and partnering across regions to deliver consistent processes and ways of working.
  • Experience in both early-stage and late-stage organizations, ideally including a transition to commercialization.
  • Proven ability to support an organization through significant change and growth.
  • Proven success partnering with executive leadership in a growth-stage or biotech/pharmaceutical environment, preferably with international exposure.
  • A strong track record in organizational design, talent management, change management, and performance optimization.
  • Deep knowledge of European human resources regulatory landscapes, including employment law, benefits, and payroll, and the ability to translate global policies to local markets.
  • Demonstrated experience leading payroll, benefits, and human resources systems across multiple European countries.
  • Fluency in German and English; proficiency in another language is a plus.
  • Ability to travel as needed.

Responsibilities

  • Act as a trusted advisor to the European leadership team on organizational design, talent strategy, workforce planning, and change management.
  • Implement people strategy aligned with business goals.
  • Lead talent reviews, succession planning, and leadership development across Europe; implement development plans for key leaders and high-potential talent.
  • Design and drive performance management, coaching, and feedback loops that foster a high-performance culture.
  • Assess and optimize organizational structure, spans of control, and governance in Europe; guide restructuring efforts as needed.
  • Lead change management initiatives as the organization prepares for commercial launch in the United States, including operational scale-up, new processes, and regulatory and commercial milestones.
  • Oversee European human resources operations, including payroll, benefits, hiring, workforce analytics, human resources systems, vendor management, and human resources service delivery.
  • Ensure global human resources policies are locally compliant, culturally adaptable, and consistently applied.
  • Influence compensation planning, incentive design, and reward structures in alignment with market benchmarks and company objectives.
  • Build and monitor human resources metrics and provide actionable insights to leadership.
  • Drive engagement initiatives and transparent communication programs across dispersed teams.
  • Foster diversity, equity, inclusion, and belonging initiatives; partner with leadership to embed culture during scale-up phases.
  • Partner closely with the United States human resources team to align processes, systems, and ways of working.
  • Partner with Legal, Finance, and Compliance to ensure consistent policy application and risk mitigation.

Desired Qualifications

  • Proficiency in a language in addition to German and English.
  • Ideally, experience with the transition to commercialization.
  • International exposure is preferred.

About the Company

Immunic Therapeutics

Clinical-stage biopharma developing oral autoimmune therapies

Immunic Therapeutics develops oral therapies for chronic inflammatory and autoimmune diseases and is in clinical-stage development. Its lead candidate, vidofludimus calcium (IMU-838), is an oral small molecule that activates the Nurr1 receptor to protect nerve cells and inhibits DHODH to calm overactive immune responses; its pipeline also includes IMU-856, a SIRT6 modulator aimed at restoring intestinal barrier function, with IMU-381 in preclinical GI programs. The company emphasizes oral, small-molecule drugs with dual actions and pursues partnerships or licensing for commercialization rather than relying on near-term product revenue. Its goal is to advance its drug candidates through clinical trials toward commercialization, potentially via collaborations with larger pharma companies.

Company size
51-200
Company stage
IPO
Headquarters
New York City, New York
Founded
2016

Recently Posted Jobs

Explore more opportunities at Immunic Therapeutics

See more jobs